Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Fate of EU drugs agency hangs in Brexit balance

February 17, 2016, Politico

Grant Castle and Robin Blaney are quoted in this Politico article discussing the potential impact of “Brexit” on the pharmaceutical sector in the UK and Europe. According to Castle, the “only rational alternative” to EU membership is for the U.K. to become a member of the European Economic Area, as this arrangement would make it so the practical and operational impact “may not be that significant” on pharmaceutical and biotech companies. 

More broadly on health policy, an EU exit, even if it remains in the economic area, would see the loss of British influence in Europe’s institutions, says Blaney. “It will become a less significant participant in EU regulatory procedures.”


Share this article: